Pyrotinib
Non Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.Small moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 73/ 100
- Competitive Position
- 65/ 100
Competitive context
203 Active assets in the Non Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine Intergroupe Francophone de Cancerologie Thoracique | Phase 4 | BB |
Osimertinib Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 4 | BB |
Nivolumab Fred Hutchinson Cancer Center | Phase 4 | BB |
rc48-adc CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 4 | BB |
Tislelizumab CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →